(Q39958508)

15 September 2017

title

Effects of fulvestrant alone or combined with different steroids in human breast cancer cells in vitro (English)

1 reference

15 September 2017

G H Jansen

1

1 reference

15 September 2017

H R Franke

2

1 reference

15 September 2017

F Wolbers

3

1 reference

15 September 2017

M Brinkhuis

4

1 reference

15 September 2017

I Vermes

5

1 reference

15 September 2017

publication date

1 August 2008

1 reference

15 September 2017

1 reference

15 September 2017

volume

11

1 reference

15 September 2017

issue

4

1 reference

15 September 2017

page(s)

315-321

1 reference

The future of fulvestrant ("Faslodex").

15 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1080%2F13697130802232500

A comparison of fulvestrant and the third-generation aromatase inhibitors in the second-line treatment of postmenopausal women with advanced breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13697130802232500

Preclinical and clinical experience with fulvestrant (Faslodex) in postmenopausal women with hormone receptor-positive advanced breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13697130802232500

Fulvestrant: pharmacologic profile versus existing endocrine agents for the treatment of breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13697130802232500

Hormone receptors and breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13697130802232500

Hormone replacement therapy for breast cancer survivors: facts versus fears

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13697130802232500

Apoptosis and proliferation in breast cancer cells, cultured in vitro: effects of SERMs

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13697130802232500

Real time quantitative PCR

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13697130802232500

A rapid and simple method for measuring thymocyte apoptosis by propidium iodide staining and flow cytometry

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13697130802232500

Flow cytometry of apoptotic cell death

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13697130802232500

HABITS (hormonal replacement therapy after breast cancer--is it safe?), a randomised comparison: trial stopped

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13697130802232500

Comparison of the effect of progesterone, medroxyprogesterone acetate and norethisterone on the proliferation of human breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13697130802232500

Menopausal hormone therapy after breast cancer: the Stockholm randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13697130802232500

Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women's Health Initiative Randomized Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13697130802232500

Is HRT justified for symptom management in women at higher risk of developing breast cancer?

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13697130802232500

Differential effects of progestogens on breast cancer cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13697130802232500

Differential effects of bisphosphonates on breast cancer cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13697130802232500

10.1080/13697130802232500

21 January 2018

Identifiers

DOI

1 reference

15 September 2017

1 reference